Category: 611-75-6

Kong, Dexian;Huang, Siqin;Cheng, Jiansong;Zhuang, Qizhao;Liu, Yijun;Lu, Chun-Hua published 《Sensitive determination of bromhexine hydrochloride based on its quenching effect on luminol/H₂O₂ electrochemiluminescence system》 in 2018. The article was appeared in 《Luminescence》. They have made some progress in their research.Quality Control of 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride The article mentions the following:

In this paper, the electrochemiluminescence (ECL) behavior of luminol/H2O2 system in the presence of bromhexine hydrochloride (BrH) was investigated. It was found that the ECL intensity of luminol/H2O2 system on a platinum electrode could be intensely quenched by BrH owing to the scavenging superoxide radical ability of BrH, and therefore the sensitive determination of BrH was possible. Under optimal conditions, the quenched ECL intensity was linear to the concentration of BrH in a wide range of 0.08 to 500μM, with a detection limit of 0.02μM (signal-to-noise ratio (S/N) = 3). This ECL method possessed the merits of rapid, simple and sensitive, and was successfully applied to the BrH quantification in pharmaceutical preparations with satisfactory recoveries of 91.0 ± 4.0 to 106.5 ± 3.4%. The possible route of the quenched ECL of luminol/H2O2 in the presence of BrH was also discussed.2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) were involved in the experimental procedure.

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) is intended to support the body’s mechanisms for clearing mucus from the respiratory tract. Bromhexine is a synthetic derivative of the herbal active ingredient vasicine. It has been shown to increase the proportion of serous bronchial secretion, making it more easily expectorated. It is indicated as secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.Quality Control of 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride

Reference:
Bromide – Wikipedia,
bromide – Wiktionary

Application In Synthesis of 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochlorideIn 2015, Attia, Khalid Abdelsalam M.;Nassar, Mohammed W. I.;Osman, Ayman published 《Different chemometric models applied for the simultaneous determination of certain drugs acting on respiratory system》. 《European Journal of Biomedical and Pharmaceutical Sciences》published the findings. The article contains the following contents:

Different Chemometric models were applied for the quant. anal. of Salbutamol (SL) and bromhexine (BH) in binary mixture, namely, Classical Least Square (CLS), Principle Component Regression (PCR), Artificial Neural Networks (ANN) as advanced model And Genetic algorithm- Artificial Neural Networks GA-ANN. The methods were used for the quant. anal. of the drugs in raw materials and pharmaceutical dosage form via handling the UV spectral data. A 2-factor 5-level exptl. design was established resulting in 25 mixtures containing different ratios of the drugs. Thirteen mixtures were used as a calibration set and the other twelve mixtures were used as validation set to validate the prediction ability of the suggested methods. The experimental procedure involved many compounds, such as 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) .

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) is intended to support the body’s mechanisms for clearing mucus from the respiratory tract. Bromhexine is a synthetic derivative of the herbal active ingredient vasicine. It has been shown to increase the proportion of serous bronchial secretion, making it more easily expectorated. It is indicated as secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.Application In Synthesis of 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride

Reference:
Bromide – Wikipedia,
bromide – Wiktionary

Synthetic Route of C14H21Br2ClN2In 2014, Hildebrand, Marcel;Hamaed, Hiyam;Namespetra, Andrew M.;Donohue, John M.;Fu, Riqiang;Hung, Ivan;Gan, Zhehong;Schurko, Robert W. published 《³⁵Cl solid-state NMR of HCl salts of active pharmaceutical ingredients: structural prediction, spectral fingerprinting and polymorph recognition》. 《CrystEngComm》published the findings. The article contains the following contents:

A series of HCl salts of active pharmaceutical ingredients (APIs) have been characterized via³⁵Cl solid-state NMR (SSNMR) spectroscopy and first-principles plane-wave d. functional theory (DFT) calculations of ³⁵Cl NMR interaction tensors. ³⁵Cl NMR spectra have been acquired at both standard (9.4 T) and high (21.1 T) magnetic field strengths, on stationary samples and under conditions of magic-angle spinning (MAS). The ³⁵Cl elec. field gradient (EFG) and chem. shift (CS) tensor parameters are readily extracted from anal. simulations of these spectra. These parameters are distinct for each sample, indicating that these spectra can be used as fingerprints for identifying unique solid phases. It is possible to correlate the ³⁵Cl EFG parameters (the quadrupolar coupling constant, C_Q, and the asymmetry parameter, η_Q) to the hydrogen-bonding environments of each chlorine anion, and several simple trends are observed ³⁵Cl EFG tensors obtained from plane-wave DFT calculations are found to be in good agreement with experiment, and unique structural insights are gained by considering the predicted EFG tensor orientations and the signs of the quadrupolar coupling constants ³⁵Cl SSNMR can be easily applied for the differentiation of polymorphs of HCl APIs, since the spectra are sensitive to even the subtlest changes in the chlorine anion environments. We discuss the application of this combination of techniques as both standalone and complementary NMR crystallog. methodologies for structural characterization and potential high-throughput screening of polymorphs of HCl APIs. The experimental procedure involved many compounds, such as 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) .

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) is intended to support the body’s mechanisms for clearing mucus from the respiratory tract. Bromhexine is a synthetic derivative of the herbal active ingredient vasicine. It has been shown to increase the proportion of serous bronchial secretion, making it more easily expectorated. It is indicated as secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.Synthetic Route of C14H21Br2ClN2

Reference:
Bromide – Wikipedia,
bromide – Wiktionary

Kajihara, Ryusuke;Noguchi, Shuji;Iwao, Yasunori;Suzuki, Yoshio;Terada, Yasuko;Uesugi, Kentaro;Itai, Shigeru published 《Structural changes of polymer-coated microgranules and excipients on tableting investigated by microtomography using synchrotron X-ray radiation》. The research results were published in《International Journal of Pharmaceutics (Amsterdam, Netherlands)》 in 2015.HPLC of Formula: 611-75-6 The article conveys some information:

Multiple-unit tablets consisting of polymer-coated microgranules and excipients have a number of advantageous pharmaceutical properties. Polymer-coated microgranules are known to often lose their functionality because of damage to the polymer coating caused by tableting, and the mechanism of polymer coating damage as well as the structural changes of excipients upon tableting had been investigated but without in-situ visualization and quant. anal. To elucidate the mechanism of coating damage, the internal structures of multiple-unit tablets were investigated by X-ray computed microtomog. using synchrotron X-rays. Cross sectional images of the tablets with sub-micron spatial resolution clearly revealed that void spaces remained around the compressed excipient particles in the tablets containing an excipient composed of cellulose and lactose (Cellactose 80), whereas much smaller void spaces remained in the tablets containing an excipient made of sorbitol (Parteck SI 150). The relationships between the void spaces and the phys. properties of the tablets such as hardness and disintegration were investigated. Damage to the polymer coating in tablets was found mainly where polymer-coated microgranules were in direct contact with each other in both types of tablets, which could be attributed to the difference in hardness of excipient particles and the core of the polymer-coated microgranules. To complete the study, the researchers used 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) .

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) (BHH; 250μM; 24 hours) also significantly attenuates HGF-induced invasion of LNCaP and C4-2B cells that natively express TMPRSS2. No significant toxicity is observed over a 48-hour period exposing LNCaP, DU145, PC3, or HepG2 cells to Bromhexine hydrochloride concentrations ranging from 0μM to 250μM. Bromhexine hydrochloride exposure does not induce cell death or substantially suppress the growth of DU145 cells.Bromhexine hydrochloride (20 μM; 48 h) inhibits dendritic cells infection with HIV-1.HPLC of Formula: 611-75-6

Reference:
Bromide – Wikipedia,
bromide – Wiktionary

Formula: C14H21Br2ClN2In 2013, Pu, Jiekun;Zhang, Kai;Hao, Xiaofei;Niu, Guizhen;Du, Yumin published 《Synthesis of bromhexine hydrochloride》. 《Zhongguo Yiyao Gongye Zazhi》published the findings. The article contains the following contents:

Bromhexine hydrochloride was synthesized from 2-amino-3,5-dibromobenzaldehyde by reduction with NaBH₄ and chlorination with SOCl₂ to give 2,4-dibromo-6-chloromethylaniline, which was subjected to amination with N-methylcyclohexylamine and salt formation. The overall yield was about 57%. The experimental procedure involved many compounds, such as 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) .

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) (BHH; 250μM; 24 hours) also significantly attenuates HGF-induced invasion of LNCaP and C4-2B cells that natively express TMPRSS2. No significant toxicity is observed over a 48-hour period exposing LNCaP, DU145, PC3, or HepG2 cells to Bromhexine hydrochloride concentrations ranging from 0μM to 250μM. Bromhexine hydrochloride exposure does not induce cell death or substantially suppress the growth of DU145 cells.Bromhexine hydrochloride (20 μM; 48 h) inhibits dendritic cells infection with HIV-1.Formula: C14H21Br2ClN2

Reference:
Bromide – Wikipedia,
bromide – Wiktionary

COA of Formula: C14H21Br2ClN2In 2020, Li, Ting;Sun, Laifang;Zhang, Wenwu;Zheng, Chanfan;Jiang, Chenchen;Chen, Mingjing;Chen, Di;Dai, Zhijuan;Bao, Shihui;Shen, Xian published 《Bromhexine hydrochloride tablets for the treatment of moderate COVID-19: an open-label randomized controlled pilot study》. 《Clinical and Translational Science》published the findings. The article contains the following contents:

This open-label randomized controlled pilot study aimed to test the study feasibility of bromhexine hydrochloride (BRH) tablets for the treatment of mild or moderate coronavirus disease 2019 (COVID-19) and to explore its clin. efficacy and safety. Patients with mild or moderate COVID-19 were randomly divided into the BRH group or the control group at a 2:1 ratio. Routine treatment according to China’s Novel Coronavirus Pneumonia Diagnosis and Treatment Plan was performed in both groups, whereas patients in the BRH group were addnl. given oral BRH (32 mg t.i.d.) for 14 consecutive days. The efficacy and safety of BRH were evaluated. A total of 18 patients with moderate COVID-19 were randomized into the BRH group (n = 12) or the control group (n = 6). There were suggestions of BRH advantage over placebo in improved chest computed tomog., need for oxygen therapy, and discharge rate within 20 days. However, none of these findings were statistically significant. BRH tablets may potentially have a beneficial effect in patients with COVID-19, especially for those with lung or hepatic injury. A further definitive large-scale clin. trial is feasible and necessary.2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) were involved in the experimental procedure.

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) is a mucolytic agent that exerts both a secretagogic action on submucosal glands and a mucolytic action toward acid glycoproteins inside cells. Bromhexine Hydrochloride is a medication prescribed for coughs which works by dissolving hard phlegm. OthersBromhexine is a mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. In addition, bromhexine has antioxidant properties. COA of Formula: C14H21Br2ClN2

Reference:
Bromide – Wikipedia,
bromide – Wiktionary

Category: bromides-buliding-blocks《HPLC simultaneous determination of four active components in sulfamethoxazole, trimethoprim, bromhexine hydrochloride and clorprenaline hydrochloride capsules》 was published in 2015. The authors were Wu, Jingfang;Li, Zhifang, and the article was included in《Zhongguo Yaopin Biaozhun》. The author mentioned the following in the article:

Objective: To establish an HPLC method for content determination of four active components in Sulfamethoxazole, Trimethoprim, Bromhexine Hydrochloride and Clorprenaline Hydrochloride Capsules. Methods: The HPLC anal. was performed on an Ecosil-C₁₈ (4.6 mm × 250 mm, 5 μm) column. The mobile phase was consisted of acetonitrile and 0.0015 mol·L^-1 sodium dodecyl sulfate of 0.1% triethylamine solution (pH was adjusted to 3.0 by phosphoric acid) (52:48) at the flow rate of 1.0 mL·min^-1. The detected wavelength was set at 215 nm. Results: Four active components were separated completely in 10 min, and had good linear relationship (r>0.9999) and recoveries (98.85%-99.58%) in their resp. detection scopes. Conclusion: The method can be applied for simultaneous determination of four active components in Sulfamethoxazole, Trimethoprim, Bromhexine Hydrochloride and Clorprenaline Hydrochloride Capsules. The experimental procedure involved many compounds, such as 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) .

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) (BHH; 250μM; 24 hours) also significantly attenuates HGF-induced invasion of LNCaP and C4-2B cells that natively express TMPRSS2. No significant toxicity is observed over a 48-hour period exposing LNCaP, DU145, PC3, or HepG2 cells to Bromhexine hydrochloride concentrations ranging from 0μM to 250μM. Bromhexine hydrochloride exposure does not induce cell death or substantially suppress the growth of DU145 cells.Bromhexine hydrochloride (20 μM; 48 h) inhibits dendritic cells infection with HIV-1.Category: bromides-buliding-blocks

Reference:
Bromide – Wikipedia,
bromide – Wiktionary

Shen, Yanfeng;Ma, Fengling;Zhu, Yanhua published 《Understanding of the check item related substance in bromhexine hydrochloride and glucose injection》. The research results were published in《Zhongguo Yaopin Biaozhun》 in 2014.COA of Formula: C14H21Br2ClN2 The article conveys some information:

A review on the understanding of the check item related substance in bromhexine hydrochloride and glucose injection. And 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) was used in the research process.

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) is intended to support the body’s mechanisms for clearing mucus from the respiratory tract. Bromhexine is a synthetic derivative of the herbal active ingredient vasicine. It has been shown to increase the proportion of serous bronchial secretion, making it more easily expectorated. It is indicated as secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.COA of Formula: C14H21Br2ClN2

Reference:
Bromide – Wikipedia,
bromide – Wiktionary

Feng, Guo published 《Improvement of quality standard of compound tulobuterol syrup》 in 2015. The article was appeared in 《Zhongguo Yaoshi (Beijing, China)》. They have made some progress in their research.Product Details of 611-75-6 The article mentions the following:

Objective: To establish a method for the assay of bromhexine hydrochloride and promethazine hydrochloride in compound tulobuterol syrup by HPLC to improve its quality standard Methods: The procedure was performed on the Agilent Eclipse Plus C18 column (250 mm × 4.6 mm, 5 μm) at 30°C, detected at 247 nm. The mobile phase was composed by a gradient of acetonitrile and 0.5% triethylamine solution (35 : 65, of which the pH was adjusted to 3.5 by phosphoric acid, fluxed at 1.0 mL·min^-1). Results: Bromhexine hydrochloride and promethazine hydrochloride were in good linear at 7.693-192.320 μg·mL^-1 (r = 0.9999), and 4.509-112.720 μg·mL^-1 (r = 0.9999), resp. The mean recoveries were 99.43% (RSD = 0.60%), and 99.34% (RSD = 0.64%) (n = 9). Conclusion: The method is proved to be specific, accurate, sensitive, simple and applicable for quality control of this product. And 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) was used in the research process.

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) is intended to support the body’s mechanisms for clearing mucus from the respiratory tract. Bromhexine is a synthetic derivative of the herbal active ingredient vasicine. It has been shown to increase the proportion of serous bronchial secretion, making it more easily expectorated. It is indicated as secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.Product Details of 611-75-6

Reference:
Bromide – Wikipedia,
bromide – Wiktionary

Yasui, Kosuke;Kamitani, Miharu;Fujimoto, Hayato;Tobisu, Mamoru published 《The Effect of the Leaving Group in N-Heterocyclic Carbene-Catalyzed Nucleophilic Aromatic Substitution Reactions》 in 2020. The article was appeared in 《Bulletin of the Chemical Society of Japan》. They have made some progress in their research.Recommanded Product: 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride The article mentions the following:

The reactivity order of the leaving group was F > Cl ≥ Br > I in N-heterocyclic carbene-catalyzed CS_NAr reactions of aryl halides bearing an α,β-unsaturated amide was discussed. Based on a qual. Marcus anal., the nature of the transition state in this catalytic CS_NAr was primarily determined by the potential energy of the Meisenheimer complex, even though it was not involved as a discrete intermediate in the reaction pathway.2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) were involved in the experimental procedure.

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) is intended to support the body’s mechanisms for clearing mucus from the respiratory tract. Bromhexine is a synthetic derivative of the herbal active ingredient vasicine. It has been shown to increase the proportion of serous bronchial secretion, making it more easily expectorated. It is indicated as secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.Recommanded Product: 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride

Reference:
Bromide – Wikipedia,
bromide – Wiktionary